The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.25
Bid: 6.00
Ask: 6.50
Change: 0.00 (0.00%)
Spread: 0.50 (8.333%)
Open: 6.25
High: 6.25
Low: 6.25
Prev. Close: 6.25
KMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Firm Placing and Open Offer

17 Aug 2015 12:11

RNS Number : 2408W
Kromek Group PLC
17 August 2015
 

17 August 2015

Kromek Group plc

("Kromek" or the "Company")

 

Results of Firm Placing and Open Offer and Result of General Meeting

 

On 30 July 2015, Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, announced a Firm Placing to raise £9 million and an Open Offer to raise up to an additional £2.0 million.

 

The Company is pleased to announce that at its General Meeting held today all of the resolutions as set out in the Circular dated 30 July 2015 were duly passed.

 

The Company is also pleased to announce the results of the Open Offer, which closed for acceptances at 11:00 a.m. on 14 August 2015. Valid acceptances have been received in respect of 9,716,307 new ordinary shares of 1 pence each (the "Ordinary Shares"), representing a percentage take up of 121 per cent of those Ordinary Shares available under the Open Offer. Qualifying Shareholders who have applied for Offer Shares will receive their full Open Offer entitlement. Shareholders that made an application under the excess application facility will receive approximately 73 per cent of new Ordinary Shares applied for.

 

The following Directors have subscribed for Ordinary Shares under the Open Offer:

 

Following Admission

Name

 

Numberof Ordinary Shares held prior to Admission

 

Numberof new Ordinary Shares subscribed for under the Open Offer

 

Numberof new Ordinary Shares subscribed for under the Excess Application Facility

 

Numberof Ordinary Shares held following Admission

 

Percentage ofEnlarged ShareCapital following Admission

 

Arnab Basu.............

2,000,000

72,000

0

2,072,000

1.36%

Max Robinson.........

9,500,000

60,000

0

9,560,000

6.28%

Graeme Speirs*........

14,792,730

922,799

552,886

16,268,415

10.69%

Brian Tanner.............

750,000

50,000

0

800,000

0.53%

 

*Prior to Admission Mr Speirs was directly interested in 3,414,940 Ordinary Shares and a further 11,377,790 Ordinary Shares through his directorship in Polymer Holdings Limited. Mr Speirs has subscribed for 80,000 Ordinary Shares through his entitlement under the Open Offer. Polymer Holdings Limited has subscribed for 842,799 Ordinary Shares through its entitlement under the Open Offer and an additional 552,886 Ordinary Shares under the excess application facility. Following Admission Mr Speirs will be directly interested in 3,494,940 Ordinary Shares and a further 12,773,475 Ordinary Shares through his directorship in Polymer Holdings Limited, representing 2.29 per cent and 8.39 per cent of the Enlarged Share Capital.

 

Accordingly, application has been made for 8,012,792 new Ordinary Shares to be issued via the Open Offer to be admitted to trading on AIM. The Company has also made application for 36,000,000 new Ordinary Shares to be issued via the Firm Placing to be admitted to trading in AIM. It is expected that Admission and commencement of dealings in the 44,012,792 new Ordinary Shares will commence at 8:00am on 18 August 2015. Following Admission, the enlarged issued share capital of the Company will consist of 152,186,082 Ordinary Shares. Therefore, the total number of voting rights in the Company is 152,186,082 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

Defined terms used in this announcement not otherwise defined shall have the same meaning as those terms defined and used in the Circular dated 30 July 2015.

 

Enquiries:

 

Kromek Group plc

01740 626 060

Arnab Basu, CEO

Derek Bulmer, CFO

Cenkos Securities plc

0207 397 8900

Bobbie Hilliam (NOMAD)

Julian Morse (Sales)

Luther Pendragon

0207 618 9100

Harry Chathli, Claire Norbury, Alexis Gore

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFILTTIDLIE
Date   Source Headline
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes
5th Feb 20247:00 amRNSKromek granted £1.3m under Horizon Europe scheme
30th Jan 20247:00 amRNSInterim Results
25th Jan 20247:00 amRNSKromek receives £1.4m CBRN order for EU stockpile
23rd Jan 20247:00 amRNSNotice of Results
18th Jan 20247:00 amRNSKromek receives $1.6m in advanced imaging orders
7th Nov 20237:00 amRNSCollaboration agreement with new CT partner
31st Oct 20237:00 amRNSKromek receives additional $1m in CBRN orders
26th Oct 20237:00 amRNSFirst US DHS Contract for Biosecurity for $5.9m
9th Oct 20234:59 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSHolding(s) in Company
28th Sep 202311:25 amRNSResult of AGM
28th Sep 20237:00 amRNSFinancing Update
14th Sep 20237:00 amRNSPartial Conversion of Convertible Loan Notes
12th Sep 20237:00 amRNSKromek detectors in new Spectrum Dynamics scanner
1st Sep 20235:00 pmRNSNotice of AGM and Publication of Annual Report
24th Jul 20237:01 amRNSFinal Results
24th Jul 20237:00 amRNSAppointment of Joint Broker
5th Jun 20237:00 amRNSNew $1.5m CBRN contract in Asia
31st May 20239:05 amRNSHolding(s) in Company
25th May 20232:48 pmRNSResult of Open Offer, General Meeting and TVR
10th May 20231:39 pmRNSNotice of Investor Webinar
5th May 20233:46 pmRNSPlacing, Subscription, Open Offer and Notice of GM
2nd May 20237:00 amRNSKromek receives medical imaging order of c.$1.4m
19th Apr 20237:00 amRNSKromek and Analogic Collaboration Agreement
18th Apr 20237:01 amRNSTrading Update
18th Apr 20237:00 amRNSSeven-Year Agreement with Tier 1 OEM
29th Mar 20237:00 amRNSKromek secures orders totalling over $1m
22nd Mar 20232:51 pmRNSHolding(s) in Company
31st Jan 20237:00 amRNSInterim Results
31st Jan 20237:00 amRNSKromek awarded c. £2.5m by Innovate UK
9th Jan 20237:00 amRNSKromek Secures $0.8m Order for D3S ID
19th Dec 20227:00 amRNSFurther agreement with Smiths Detection
15th Dec 20229:32 amEQSKromek Group 'delighted' with new contracts
12th Dec 20227:00 amRNSKromek wins £1.5m in nuclear security contracts
16th Nov 20227:00 amRNSAward of £5m bio-threat contract by UK Government
10th Nov 20227:00 amRNSKromek awarded US nuclear security contract
17th Oct 202211:42 amRNSKromek detectors used in digital SPECT/CT scanner
28th Sep 202212:27 pmRNSResult of AGM
2nd Sep 20225:26 pmRNSNotice of AGM and Publication of Annual Report
23rd Aug 202211:10 amRNSFundraising of £1.14 million
5th Aug 20227:00 amRNSFundraising of £1.7m
3rd Aug 20222:05 pmRNSSecond Price Monitoring Extn
3rd Aug 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.